We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

235 hedge funds and large institutions have $2.67B invested in Amicus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 85 increasing their positions, 73 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

237% more call options, than puts

Call options by funds: $18.8M | Put options by funds: $5.59M

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

16% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 73

3% less capital invested

Capital invested by funds: $2.74B → $2.67B (-$68.9M)

1.98% less ownership

Funds ownership: 106.07%104.09% (-2%)

9% less funds holding

Funds holding: 259235 (-24)

41% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 54

Holders
235
Holders Change
-24
Holders Change %
-9.27%
% of All Funds
4.09%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
32
Increased
85
Reduced
73
Closed
54
Calls
$18.8M
Puts
$5.59M
Net Calls
+$13.2M
Net Calls Change
+$8.3M

FOLD Hedge Fund Activity: Q2 2021 in Review

235 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2021, worth a combined $2.67B — down 2.5% from $2.74B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of FOLD and 32 opened new positions — a net loss of 22 holders — while 73 trimmed existing stakes and 85 added.

The largest buyer was Point72 Asset Management, adding an estimated $36M. The largest seller was Janus Henderson Group, cutting an estimated $39M.

  • 235 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2021, down from 259 in Q1 2021.
  • Funds reported $2.67B of Amicus Therapeutics stock for Q2 2021, down 2.5% quarter-over-quarter.
  • 32 funds opened new Amicus Therapeutics positions in Q2 2021 and 54 closed out, a net change of -22 holders.
  • The largest Amicus Therapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $36M added.
  • The largest Amicus Therapeutics seller in Q2 2021 was Janus Henderson Group, an estimated $39M sold.

Based on aggregated 13F filings for Q2 2021.